Related Experiment Video
Updated: Jun 26, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based
Wei Zhang1, Jibin Li, Samantha M Allen
1Absorption Systems, LP, 436 Creamery Way, Suite 600, Exton, PA 19341, USA.
Abstract:
A series of stable breast cancer resistance protein (BCRP, ABCG2) knockdown cell lines were produced by transduction of Caco-2 cells with lentiviral vector-based short hairpin RNA (shRNA). Caco-2 cell is a human intestinal-derived cell line widely used to study intestinal drug absorption. Caco-2 expresses three apical drug efflux transporters: BCRP, P-glycoprotein (P-gp; ABCB1), and multidrug resistance protein 2 (MRP2, ABCC2). BCRP and P-gp in particular play a significant role in pharmacokinetics because of their expression at several key interfaces. Overexpression of BCRP in cancer cells may also be a mechanism of tumor resistance to chemotherapeutic drugs. The goal of this study was to engineer and characterize Caco-2 cell clones with stable knockdown of BCRP expression. The shRNA/BCRP lentiviral particles were used to infect a stable clone of Caco-2 cells. Expression of BCRP was monitored using quantitative polymerase chain reaction (qPCR), Western blotting, immunofluorescence microscopy, and bidirectional transport of probe substrates, estrone-3-sulfate (E3S), and pheophorbide A (PhA). Based on qPCR, expression of BCRP mRNA was knocked down in five clones with a maximum of 97% silencing in clone D. Silencing of BCRP gene expression was maintained for at least 25 passages. Expression of BCRP protein was also reduced significantly. Functionally, BCRP knockdown was reflected in significant reduction of the efflux ratio of E3S and PhA. Clone D in particular should be a useful model for identifying and characterizing P-gp substrates and inhibitors without interference from BCRP and/or MRP2. In addition, it can be used in conjunction with wild-type or vector control Caco-2 cells to identify BCRP substrates.
Insights
Stable knockdown cell lines for breast cancer resistance protein (BCRP) were created using shRNA in Caco-2 cells. These engineered cells, particularly clone D, are valuable tools for studying drug transporters and their impact on pharmacokinetics and cancer drug resistance.
Area of Science:
- Pharmacology
- Molecular Biology
- Cell Biology
Background:
- Caco-2 cells are a human intestinal model crucial for studying drug absorption.
- Breast cancer resistance protein (BCRP, ABCG2) and P-glycoprotein (P-gp, ABCB1) are key efflux transporters impacting drug pharmacokinetics.
- BCRP overexpression in cancer can lead to chemotherapeutic drug resistance.
Purpose of the Study:
- To engineer and characterize Caco-2 cell clones with stable knockdown of BCRP expression.
- To develop a reliable cellular model for investigating BCRP's role in drug transport and resistance.
- To facilitate the identification of BCRP substrates and inhibitors.
Main Methods:
- Lentiviral vector-based short hairpin RNA (shRNA) was used to stably transduce Caco-2 cells.
- BCRP expression was quantified using qPCR, Western blotting, and immunofluorescence microscopy.
- Bidirectional transport assays with estrone-3-sulfate (E3S) and pheophorbide A (PhA) were performed.
Main Results:
- Five stable BCRP knockdown Caco-2 cell clones were generated, with up to 97% mRNA silencing in clone D.
- Gene silencing was stable for at least 25 passages, with significant protein reduction observed.
- Knockdown resulted in a reduced efflux ratio for E3S and PhA, confirming functional BCRP inhibition.
Conclusions:
- Engineered Caco-2 cell clones with stable BCRP knockdown provide a valuable tool for drug transport studies.
- Clone D is particularly useful for P-gp substrate/inhibitor identification without BCRP interference.
- These cell lines aid in understanding BCRP's role in drug absorption and cancer resistance.
Related Concept Videos
Experimental RNAi
MicroRNAs
MicroRNAs

